You are here

Merck tops profit estimates on Keytruda sales

[BENGALURU] Merck & Co on Friday reported a quarterly profit that beat analysts' estimates, benefiting from sales of its immuno-oncology drug Keytruda.

Sales of Keytruda, which were helped by approval across various indications this year, were US$1.05 billion for the third quarter, in line with Leerink consensus estimates.

Merck's shares were up 1.8 per cent at US$63.10 before the bell.

Net loss attributable to Merck was US$56 million, or 2 US cents per share, in the third quarter, compared with a year-ago profit of US $2.18 billion, or 78 US cents per share.

Merck had a US$2.35 billion charge related to its collaboration with AstraZeneca, which it had announced in the second quarter.

Your feedback is important to us

Tell us what you think. Email us at btuserfeedback@sph.com.sg

Excluding items, Merck earned US$1.11 per share, beating analysts' average estimate of US$1.03, according to Thomson Reuters.

However, sales fell to US$10.33 billion from US$10.54 billion, hurt by the NotPetya cyber attack in the second quarter, which had disrupted its manufacturing operations.

The drugmaker also narrowed and raised its full-year adjusted earnings per share forecast to US$3.91-US$3.97 from US$3.76-US$3.88.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes